Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223920 | 0.86 | LMNA (0.47) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL8063816 | 0.83 | LMNA (0.52) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL13790939 | 0.83 | ACHE (0.50) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL13791121 | 0.83 | ACHE (0.50) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL30549089 | 0.81 | LMNA (0.50) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL20508719 | 0.81 | ACHE (0.48) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL18551444 | 0.81 | ACHE (0.48) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL20076063 | 0.81 | ACHE (0.48) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL9987208 | 0.81 | CYP3A4 (0.50) | LMNAMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL9987204 | 0.81 | CYP3A4 (0.50) | LMNAMTNR1AMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321287-B1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-8729113-B2 | 4,5-dihydro-oxazol-2yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8357712-B2 | — | — | 2013-01-22 | — | — | US | disclosed |
| US-8242153-B2 | 4,5-dihydro-oxazol-2YL derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120165294-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | GALLEY GUIDO (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20110144333-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | GALLEY GUIDO | 2011-06-16 | — | — | US | disclosed |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2010-02-04 | — | — | US | disclosed |
| US-5010198-A | Intermediates for the synthesis of benzoxazol- and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-23 | — | — | US | disclosed |
| EP-0184257-B1 | BENZOXAZOL- AND BENZOTHIAZOLAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-25 | — | — | EP | disclosed |
| US-4861785-A | Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-29 | — | — | US | disclosed |
| EP-0184257-A1 | Benzoxazol- and benzothiazolamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144333-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | LMNA 3212/4885ACHE 1069/4885SMN1; SMN2 1991/4885 |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | LMNA 3212/4885ACHE 1069/4885SMN1; SMN2 1991/4885 |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | LMNA 3212/4885ACHE 1069/4885SMN1; SMN2 1991/4885 |
| US-20120165294-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | LMNA 3212/4885ACHE 1069/4885SMN1; SMN2 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.